跳至主要内容
临床试验/NCT02724345
NCT02724345已完成不适用

The Effect of Postoperative Adjuvant TACE Treatment in CK18 Positive Patients of Hepatocellular Carcinoma.

Eastern Hepatobiliary Surgery Hospital1 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2013年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
320
试验地点
1
主要终点
Overall survival

研究概览

简要总结

To evaluate and analyse the clinical effect and application value of postoperative adjuvant TACE treatment in patients with different expression levels of CK18 using randomized controlled study and provide evidence for the necessity of postoperative adjuvant TACE.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Via clinical diagnosis and confirm it is primary liver cancer
  • Pathological evidence of HCC
  • Estimate tumor can gain treatment of curing operation
  • No evidence for extrahepatic metestasis
  • liver function :Child-Pugh A/B

排除标准

  • reject to attend;
  • impossible to come to our hospital for physical examination regularly.
  • cancer epitome、seed focus、lymph node or distant metastasis
  • Blood clotting function hindrance; 5, Patients with other diseases which may affect the treatment mentioned.

结局指标

主要结局

Overall survival

时间窗: 3 years

次要结局

  • Time to recurrence(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

ShenFeng

vice president of the Eastern Hepatobiliary Surgery Hospital

Eastern Hepatobiliary Surgery Hospital

研究点 (1)

Loading locations...

相似试验